Rami Komrokji, MD

Rami Komrokji, MD, presents to the panel a second clinical scenario of a 74-year-old with cytopenic myelofibrosis.

A look at the potential treatment options for a patient with myelofibrosis who progresses after first-line therapy.

Key opinion leaders discuss how they would approach treating a 67-year-old with myelofibrosis, presenting with splenomegaly.

Drs Palmer and Mesa explain the challenges of treating accelerated phase myeloproliferative neoplasms.

The panel reviews other exciting novel agents under investigation for myelofibrosis treatment.

Ruben Mesa, MD, discusses updates on the novel agent momelotinib from an abstract he presented at ASCO 2022.

Jamile Shammo, MD, FACP, explains the efficacy and safety of the 3 approved therapies for myelofibrosis.

Experts discuss data on the recently approved agents fedratinib and pacritinib for myelofibrosis treatment.

A review of data on the use of the JAK inhibitor ruxolitinib for patients with myelofibrosis.

The panel has a conversation on risk stratification for myelofibrosis and how it individualizes their treatment approaches.

Dr Jamile Shammo explains the process of diagnosing myelofibrosis and highlights the importance of bone marrow biopsies.

A discussion on assessing symptom burden and quality of life for patients with essential thrombocythemia or polycythemia vera.

Ruben Mesa, MD, details an abstract presented at ASCO 2022 on an investigational agent filling an unmet need in polycythemia vera.

An overview of the treatment options for patients with polycythemia vera.

Jamile Shammo, MD, FACP, FASCP, defines polycythemia vera and explains the process for diagnosis and risk stratification.

Dr Ruben Mesa describes how he treats patients with essential thrombocythemia and the available treatment options.

Jeanne Palmer, MD, explains essential thrombocythemia and how it’s diagnosed.

The panel of experts highlight promising clinical trials for the treatment of myelodysplastic syndrome.

Amy DeZern, MD, MHS leads a discussion surrounding the mechanism of action and clinical trial data on the use of magrolimab and pevonedistat in patients with high-risk myelodysplastic syndrome.

Rami Komrokji, MD and Gail Roboz, MD, discuss treatment considerations and clinical trial data surrounding the use of venetoclax in patients with myelodysplastic syndrome or acute myeloid leukemia.

Azra Raza, MD, discusses considerations for use of hypomethylating agents in older patients with high-risk myelodysplastic syndrome.

The panel of experts comment on the role of transplant in patients with myelodysplastic syndrome.

The panel of experts comment on the optimal timing of hypomethylating agents and transplant in patients with high-risk myelodysplastic syndrome.

The panel of experts highlight the risk factors and considerations for use of hypomethylating agents in patients with myelodysplastic syndrome versus acute myeloid leukemia.

The panel of experts reflect on the use of lenalidomide in patients with myelodysplastic syndrome who are transfusion dependent.

Rami Komrokji, MD discusses the recent approval and FDA indication for the use of the erythroid maturation agent luspatercept.

The panel of experts discusses considerations necessary when recommending treatment with erythropoiesis-stimulating agents in patients with myelodysplastic syndrome.

Rami Komrokji, MD, discusses his approach to treatment in patients with myelodysplastic syndrome, while being mindful of recommended guidelines.

The panel of leukemia experts highlight the importance of individualized treatments for patients with myelodysplastic syndrome.

Rami Komrokji, MD, and Gail Roboz, MD, discuss the importance of staging models in the diagnosis and routine assessment of patients with myelodysplastic syndrome.